Brokerages Set Atossa Genetics Inc. (NASDAQ:ATOS) Price Target at $20.33

Atossa Genetics Inc. (NASDAQ:ATOS) has been assigned an average recommendation of “Hold” from the five analysts that are currently covering the firm, MarketBeat Ratings reports. Two analysts have rated the stock with a sell rating and three have assigned a buy rating to the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $20.3333.

ATOS has been the subject of a number of research reports. Rodman & Renshaw assumed coverage on Atossa Genetics in a research report on Tuesday, July 7th. They set a “buy” rating and a $12.00 price objective for the company. Ascendiant Capital Markets dropped their target price on Atossa Genetics from $120.00 to $24.00 and set a “buy” rating on the stock in a research report on Friday, April 10th. Weiss Ratings downgraded Atossa Genetics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, June 11th. Finally, HC Wainwright lifted their price target on Atossa Genetics to $25.00 and gave the company a “buy” rating in a report on Thursday, March 26th.

Atossa Genetics Stock Performance

Atossa Genetics stock opened at $2.40 on Tuesday. Atossa Genetics has a twelve month low of $1.70 and a twelve month high of $19.35. The firm has a market cap of $20.66 million, a PE ratio of -0.75 and a beta of 1.25. The firm’s 50 day moving average price is $3.70 and its two-hundred day moving average price is $5.43.

Atossa Genetics (NASDAQ:ATOS) last issued its earnings results on Friday, May 8th. The company reported ($1.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.99) by ($0.12). Equities analysts anticipate that Atossa Genetics will post -4.3 EPS for the current fiscal year.

Institutional Trading of Atossa Genetics

A number of institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. increased its stake in shares of Atossa Genetics by 4.2% during the 3rd quarter. Vanguard Group Inc. now owns 6,078,844 shares of the company’s stock worth $5,270,000 after purchasing an additional 245,717 shares during the last quarter. Ameriprise Financial Inc. acquired a new stake in shares of Atossa Genetics in the 2nd quarter valued at $2,468,000. Renaissance Technologies LLC lifted its stake in shares of Atossa Genetics by 33.2% in the 4th quarter. Renaissance Technologies LLC now owns 2,062,838 shares of the company’s stock valued at $1,217,000 after purchasing an additional 514,175 shares during the last quarter. Geode Capital Management LLC boosted its holdings in Atossa Genetics by 0.7% in the fourth quarter. Geode Capital Management LLC now owns 1,371,909 shares of the company’s stock worth $810,000 after purchasing an additional 9,627 shares in the last quarter. Finally, State Street Corp boosted its holdings in Atossa Genetics by 31.2% in the fourth quarter. State Street Corp now owns 596,485 shares of the company’s stock worth $352,000 after purchasing an additional 141,990 shares in the last quarter. 12.74% of the stock is currently owned by institutional investors and hedge funds.

Atossa Genetics Company Profile

Atossa Genetics, Inc is a clinical-stage biotechnology company based in Seattle, Washington, focused on developing therapeutics and diagnostic products for breast cancer and other breast-related conditions. The company’s mission centers on delivering targeted, minimally invasive solutions that address early detection, treatment, and prevention in women at risk for or diagnosed with breast malignancies.

The company’s pipeline includes Z-Endoxifen, an oral formulation of endoxifen designed to treat and prevent estrogen receptor–positive breast cancers, particularly in patients with ductal carcinoma in situ or those at high risk of recurrence.